Revelation Biosciences Announces Initiation of GMP Manufacturing of GEMINI and Placebo to Support Later Stage Clinical Development

Core Insights - Revelation Biosciences, Inc. has commenced GMP manufacturing of GEMINI and placebo, which is essential for later stage clinical studies [1][2] - The CEO emphasized the importance of this manufacturing run in advancing the company's pipeline and expediting clinical programs [2] - The company recently met with the FDA to discuss the clinical development and regulatory approval pathway for GEMINI as a treatment for acute kidney injury (AKI) [3] Company Overview - Revelation Biosciences is a clinical-stage life sciences company focused on rebalancing inflammation through its proprietary formulation, GEMINI [7] - GEMINI is a toll-like receptor 4 (TLR4) agonist aimed at treating acute and chronic diseases related to dysregulated inflammation [4] - The company is evaluating GEMINI for multiple applications, including acute kidney injury, chronic kidney disease, severe burn-related hyperinflammation, and post-surgical infection prevention [4] Industry Context - Acute Kidney Injury (AKI) affects over 10% of hospitalized patients and more than 50% of ICU admissions, highlighting the need for new therapies [6] - AKI can lead to severe complications, including chronic kidney disease and increased mortality rates, underscoring the urgency for effective treatments [5][6]